The Evaluation of Eazyplex® SuperBug CRE Assay Usefulness for the Detection of ESBLs and Carbapenemases Genes Directly from Urine Samples and Positive Blood Cultures
Abstract
:1. Introduction
2. Results
3. Discussion
4. Materials and Methods
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Findlay, J.; Hopkins, K.L.; Meunier, D.; Woodford, N. Evaluation of Three Commercial Assays for Rapid Detection of Genes Encoding Clinically Relevant Carbapenemases in Cultured Bacteria. J. Antimicrob. Chemother. 2015, 70, 1338–1342. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sękowska, A.; Bogiel, T.; Gospodarek-Komkowska, E. Evaluation of Eazyplex® SuperBug CRE Test for Beta-Lactamase Genes Detection in Klebsiella spp. and P. Aeruginosa Strains. Curr. Microbiol. 2020, 77, 99–103. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Xu, L.; Sun, X.; Ma, X. Systematic Review and Meta-Analysis of Mortality of Patients Infected with Carbapenem-Resistant Klebsiella pneumoniae. Ann. Clin. Microbiol. Antimicrob. 2017, 16, 18. [Google Scholar] [CrossRef] [Green Version]
- van der Zwaluw, K.; de Haan, A.; Pluister, G.N.; Bootsma, H.J.; de Neeling, A.J.; Schouls, L.M. The Carbapenem Inactivation Method (CIM), a Simple and Low-Cost Alternative for the Carba NP Test to Assess Phenotypic Carbapenemase Activity in Gram-Negative Rods. PLoS ONE 2015, 10, e0123690. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dhesi, Z.; Enne, V.I.; O’Grady, J.; Gant, V.; Livermore, D.M. Rapid and Point-of-Care Testing in Respiratory Tract Infections: An Antibiotic Guardian? ACS Pharm. Transl. Sci. 2020, 3, 401–417. [Google Scholar] [CrossRef]
- Carter, D.; Charlett, A.; Conti, S.; Robotham, J.V.; Johnson, A.P.; Livermore, D.M.; Fowler, T.; Sharland, M.; Hopkins, S.; Woodford, N.; et al. A Risk Assessment of Antibiotic Pan-Drug-Resistance in the UK: Bayesian Analysis of an Expert Elicitation Study. Antibiotics 2017, 6, 9. [Google Scholar] [CrossRef] [Green Version]
- Abdeta, A.; Bitew, A.; Fentaw, S.; Tsige, E.; Assefa, D.; Lejisa, T.; Kefyalew, Y.; Tigabu, E.; Evans, M. Phenotypic Characterization of Carbapenem Non-Susceptible Gram-Negative Bacilli Isolated from Clinical Specimens. PLoS ONE 2021, 16, e0256556. [Google Scholar] [CrossRef]
- García-Fernández, S.; García-Castillo, M.; Melo-Cristino, J.; Pinto, M.F.; Gonçalves, E.; Alves, V.; Vieira, A.R.; Ramalheira, E.; Sancho, L.; Diogo, J.; et al. In Vitro Activity of Ceftolozane-Tazobactam against Enterobacterales and Pseudomonas Aeruginosa Causing Urinary, Intra-Abdominal and Lower Respiratory Tract Infections in Intensive Care Units in Portugal: The STEP Multicenter Study. Int. J. Antimicrob. Agents 2020, 55, 105887. [Google Scholar] [CrossRef]
- Hinić, V.; Ziegler, J.; Straub, C.; Goldenberger, D.; Frei, R. Extended-Spectrum β-Lactamase (ESBL) Detection Directly from Urine Samples with the Rapid Isothermal Amplification-Based Eazyplex® SuperBug CRE Assay: Proof of Concept. J. Microbiol. Methods 2015, 119, 203–205. [Google Scholar] [CrossRef]
- Fiori, B.; D’Inzeo, T.; Posteraro, B.; Menchinelli, G.; Liotti, F.M.; De Angelis, G.; De Maio, F.; Fantoni, M.; Murri, R.; Scoppettuolo, G.; et al. Direct Use of Eazyplex® SuperBug CRE Assay from Positive Blood Cultures in Conjunction with Inpatient Infectious Disease Consulting for Timely Appropriate Antimicrobial Therapy in Escherichia coli and Klebsiella pneumoniae Bloodstream Infections. Infect. Drug Resist. 2019, 12, 1055–1062. [Google Scholar] [CrossRef] [Green Version]
- Rödel, J.; Bohnert, J.A.; Stoll, S.; Wassill, L.; Edel, B.; Karrasch, M.; Löffler, B.; Pfister, W. Evaluation of Loop-Mediated Isothermal Amplification for the Rapid Identification of Bacteria and Resistance Determinants in Positive Blood Cultures. Eur. J. Clin. Microbiol. Infect. Dis. 2017, 36, 1033–1040. [Google Scholar] [CrossRef]
- Bach, K.; Edel, B.; Höring, S.; Bartoničkova, L.; Glöckner, S.; Löffler, B.; Bahrs, C.; Rödel, J. Performance of the Eazyplex® BloodScreen GN as a Simple and Rapid Molecular Test for Identification of Gram-Negative Bacteria from Positive Blood Cultures. Eur. J. Clin. Microbiol. Infect. Dis. 2021. [Google Scholar] [CrossRef]
- Guiral, E.; Pons, M.J.; Vubil, D.; Marí-Almirall, M.; Sigaúque, B.; Soto, S.M.; Alonso, P.L.; Ruiz, J.; Vila, J.; Mandomando, I. Epidemiology and Molecular Characterization of Multidrug-Resistant Escherichia coli Isolates Harboring BlaCTX-M Group 1 Extended-Spectrum β-Lactamases Causing Bacteremia and Urinary Tract Infection in Manhiça, Mozambique. Infect. Drug Resist. 2018, 11, 927–936. [Google Scholar] [CrossRef] [Green Version]
- D’Andrea, M.M.; Arena, F.; Pallecchi, L.; Rossolini, G.M. CTX-M-Type β-Lactamases: A Successful Story of Antibiotic Resistance. Int. J. Med. Microbiol. 2013, 303, 305–317. [Google Scholar] [CrossRef]
- Dikoumba, A.-C.; Onanga, R.; Boundenga, L.; Bignoumba, M.; Ngoungou, E.-B.; Godreuil, S. Prevalence and Characterization of Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae in Major Hospitals in Gabon. Microb. Drug Resist. 2021, 27, 1525–1534. [Google Scholar] [CrossRef] [PubMed]
- Abrar, S.; Vajeeha, A.; Ul-Ain, N.; Riaz, S. Distribution of CTX-M Group I and Group III β-Lactamases Produced by Escherichia coli and Klebsiella pneumoniae in Lahore, Pakistan. Microb. Pathog. 2017, 103, 8–12. [Google Scholar] [CrossRef] [PubMed]
- Choudhury, K.; Dhar Chanda, D.; Bhattacharjee, A. Molecular Characterization of Extended Spectrum Beta Lactamases in Clinical Isolates of Escherichia coli and Klebsiella Spp from a Tertiary Care Hospital of South Eastern Assam. Indian J. Med. Microbiol. 2021, in press. [CrossRef] [PubMed]
- Jarlier, V.; Nicolas, M.H.; Fournier, G.; Philippon, A. Extended Broad-Spectrum Beta-Lactamases Conferring Transferable Resistance to Newer Beta-Lactam Agents in Enterobacteriaceae: Hospital Prevalence and Susceptibility Patterns. Rev. Infect. Dis. 1988, 10, 867–878. [Google Scholar] [CrossRef]
- Nordmann, P.; Poirel, L.; Dortet, L. Rapid Detection of Carbapenemase-Producing Enterobacteriaceae. Emerg. Infect. Dis. 2012, 18, 1503–1507. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Genie® II. OptiGene. Available online: http://www.optigene.co.uk/wp-content/uploads/2014/07/Genie%20II%20Mark%20II%20Manual%20version%201.00.pdf (accessed on 12 May 2019).
- Nordmann, P.; Poirel, L.; Carrër, A.; Toleman, M.A.; Walsh, T.R. How to Detect NDM-1 Producers. J. Clin. Microbiol. 2011, 49, 718–721. [Google Scholar] [CrossRef] [Green Version]
- Pitout, J.D.D.; Gregson, D.B.; Poirel, L.; McClure, J.-A.; Le, P.; Church, D.L. Detection of Pseudomonas Aeruginosa Producing Metallo-Beta-Lactamases in a Large Centralized Laboratory. J. Clin. Microbiol. 2005, 43, 3129–3135. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Species Recovered from the Samples | Beta-Lactamases Genes Detected by Eazyplex® | No. of Isolates | Time of Particular Genes Detection by Eazyplex® (min:s) | Double Disc Synergy Test Result | Carba NP Test Result |
---|---|---|---|---|---|
K. pneumoniae (n = 40) | CTX-M-1 | 32 | 4:30–10:15 | (+) | N/A |
CTX-M-1, CTX-M-9 | 2 | 5:30–8:30 | (+) | N/A | |
CTX-M-1, NDM | 3 | 5:15–15:15 | (+) | (+) | |
Negative result | 2 | - | UI | N/A | |
Invalid test | 1 | - | (+) | N/A | |
E. coli (n = 13) | CTX-M-1 | 9 | 6:30–11:45 | (+) | N/A |
CTX-M-9 | 3 | 7:00–8:45 | (+) | N/A | |
CTX-M1, VIM | 1 | 5:30, 9:15 | (+) | (+) | |
E. cloacae (n = 3) | CTX-M-1 | 2 | 6:45–7:00 | (+) | N/A |
CTX-M-1, VIM | 1 | 6:00, 8:15 | (+) | (+) | |
K. oxytoca (n = 3) | CTX-M-1 | 1 | 9:45 | (+) | N/A |
CTX-M-9 | 1 | 7:00 | (+) | N/A | |
Invalid test | 1 | - | (+) | N/A | |
K. variicola (n = 1) | CTX-M1 | 1 | 7:30 | (+) | N/A |
Species Recovered from the Samples | Eazyplex® SuperBug CRE Assay | No. of Isolates | Standard PCR | No. of Isolates |
---|---|---|---|---|
K. pneumoniae (n = 40) | CTX-M-1 CTX-M-1, CTX-M-9 CXT-M1, CTX-M-9 CTX-M-1, NDM Negative result Negative result Invalid test | 32 1 1 3 1 1 1 | CTX-M, TEM, SHV CTX-M, TEM CTX-M CTX-M, TEM, SHV CTX-M, TEM CTX-M, NDM CTX-M, TEM, SHV TEM CTX-M, TEM, SHV | 23 6 3 1 1 3 1 1 1 |
K. oxytoca (n = 3) | CTX-M-1 CTX-M-9 Invalid test | 1 1 1 | CTX-M CTX-M CTX-M, TEM | 1 1 1 |
K. variicola (n = 1) | CTX-M-1 | 1 | CTX-M | 1 |
Species Recovered from the Samples | Beta-Lactamases Genes Detected by Eazyplex® | No. of Isolates | Time of Particular Genes Detection by Eazyplex® (min:s) | Double Disc Synergy Test Result | Carba NP Test Result |
---|---|---|---|---|---|
K. pneumoniae (n = 46) | CTX-M-1 | 39 | 4:30–10:15 | (+) | N/A |
CTX-M-1, CTX-M-9, NDM | 1 | 4:45–5:15 | (+) | (+) | |
CTX-M-1, NDM | 3 | 4:45–11:45 | (+) | (+) | |
KPC | 1 | 9:15 | UI | (+) | |
Negative result | 1 | - | (+) | N/A | |
Invalid test | 1 | - | (+) | N/A | |
E. cloacae (n = 3) | CTX-M-1 | 3 | 6:15–7:30 | (+) | N/A |
E. coli (n = 3) | CTX-M-1 | 1 | 7 | (+) | N/A |
CTX-M-9 | 1 | 8:15 | (+) | N/A | |
Invalid test | 1 | - | (+) | N/A | |
K. oxytoca (n = 3) | CTX-M-1 | 3 | 6–7:15 | (+) | N/A |
S. marcescens (n = 2) | CXT-M-1 | 1 | 6:30 | (+) | N/A |
Negative result | 1 | - | (+) | N/A | |
C. freundii (n = 2) | CTX-M-1 | 2 | 6–7 | (+) | N/A |
P. mirabilis (n = 1) | Invalid test | 1 | - | (+) | N/A |
Species Recovered from the Samples | Eazyplex® SuperBug CRE Assay | No. of Isolates | Standard PCR | No. of Isolates |
---|---|---|---|---|
K. pneumoniae (n = 45) | CTX-M-1 CTX-M-1, CTX-M-9, NDM CTX-M-1, NDM Negative result Invalid test | 39 1 3 1 1 | CTX-M, TEM, SHV CTX-M CTX-M, TEM CTX-M, SHV CTX-M, NDM CTX-M, NDM CTX-M, TEM, SHV, NDM TEM CTX-M | 22 8 7 2 1 2 1 1 1 |
K. oxytoca (n = 3) | CTX-M-1 | 3 | CTX-M | 3 |
S. marcescens (n = 2) | CXT-M-1 Negative result | 1 1 | CTX-M CTX-M, TEM | 1 1 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Sękowska, A.; Bogiel, T. The Evaluation of Eazyplex® SuperBug CRE Assay Usefulness for the Detection of ESBLs and Carbapenemases Genes Directly from Urine Samples and Positive Blood Cultures. Antibiotics 2022, 11, 138. https://doi.org/10.3390/antibiotics11020138
Sękowska A, Bogiel T. The Evaluation of Eazyplex® SuperBug CRE Assay Usefulness for the Detection of ESBLs and Carbapenemases Genes Directly from Urine Samples and Positive Blood Cultures. Antibiotics. 2022; 11(2):138. https://doi.org/10.3390/antibiotics11020138
Chicago/Turabian StyleSękowska, Alicja, and Tomasz Bogiel. 2022. "The Evaluation of Eazyplex® SuperBug CRE Assay Usefulness for the Detection of ESBLs and Carbapenemases Genes Directly from Urine Samples and Positive Blood Cultures" Antibiotics 11, no. 2: 138. https://doi.org/10.3390/antibiotics11020138
APA StyleSękowska, A., & Bogiel, T. (2022). The Evaluation of Eazyplex® SuperBug CRE Assay Usefulness for the Detection of ESBLs and Carbapenemases Genes Directly from Urine Samples and Positive Blood Cultures. Antibiotics, 11(2), 138. https://doi.org/10.3390/antibiotics11020138